| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-01-16 | Foundation Medicine (USA - MA) Pfizer (USA - NY) | companion diagnostics (CDx) that will be included in updates to FoundationOne CDx™. FoundationOne CDx is Foundation Medicine's FDA-approved comprehensive genomic profiling (CGP) assay for all solid tumors that incorporates multiple companion diagnostics. | Cancer - Oncology | Collaboration agreement | ||
| 2018-01-15 | Avacta (UK) Glythera (UK) | highly targeted bio-therapeutics | collaboration | Technology - Services | Licensing agreement | |
| 2018-01-11 | Boehringer Ingelheim (Germany) Pharmaxis (Australia) | PXS4728A/BI 1467335 | NASH (non-alcoholic steatohepatitis) chronic obstructive pulmonary disease (COPD) | licensing - development - production - manufacturing - commercialisation | Liver diseases - Hepatic diseases - Inflammatory diseases - Pulmonary diseases - Respiratory diseases | Milestone |
| 2018-01-10 | Ipsen (France) | vice-president | nomination | Cancer - Oncology - Rare diseases - Neurological diseases | Nomination | |
| 2018-01-10 | Aimmune Therapeutics (USA - CA) Archer Daniels Midland (USA -IL) | peanuts and tree nuts and exclusively supplies the starting material for AR101 | peanut allergy | production - manufacturing | Allergic diseases | Production agreement |
| 2018-01-10 | Basilea Pharmaceutica (Switzerland) Pfizer (USA - NY) | Cresemba® (isavuconazole) | life-threatening invasive mold infections | licensing | Infectious diseases | Licensing agreement |
| 2018-01-09 | BeiGene (China) Boehringer Ingelheim (Germany) | tislelizumab (BGB-A317) | production - manufacturing | Technology - Services | Production agreement | |
| 2018-01-08 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | bispecific antibodies and monoclonal antibodies including REGN3500, dupilumab and programmed cell death protein 1 (PD-1) inhibitor cemiplimab | collaboration - development - commercialisation | Allergic diseases - Cancer - Oncology | Collaboration agreement | |
| 2018-01-08 | Five Prime Therapeutics (USA - CA) BMS (USA - NY) | immuno-oncology therapies directed toward targets in three undisclosed immune checkpoint pathways | R&D - development - commercialisation | Cancer - Oncology | Milestone | |
| 2018-01-08 | GSK (UK) Regeneron Pharmaceuticals (USA - NY) UK Biobank (UK) IBM Watson Health (USA) Abbvie (USA - IL) Alnylam Pharmaceuticals (USA - MA) AstraZEneca (UK) Biogen (USA - MA) Pfizer (USA - NY) | genetic exome sequence data | collaboration - research | Technology - Services | Collaboration agreement | |
| 2018-01-08 | Innate Pharma (France) | chief scientific officer | nomination | Cancer - Oncology - Immunological diseases | Nomination | |
| 2018-01-08 | Heidelberg Pharma (Germany) Advanced Proteome Therapeutics (Canada) | antibody-drug conjugates (ADCs) | collaboration | Cancer - Oncology | Milestone | |
| 2018-01-08 | Adaptimmune (UK) Cell and Gene Therapy Catapult (UK) | SPEAR T-cell therapies | production - manufacturing | Technology - Services | Production agreement | |
| 2018-01-08 | Bioaster (France) Sanofi Pasteur (France) | MOSAIC (MOlecular Signatures of Adjuvanted vaccIne Candidates) project | collaboration - research | Infectious diseases | Collaboration agreement | |
| 2018-01-08 | BeiGene (China) Mirati Therapeutics (USA - CA) | sitravatinib | non-small cell lung cancer (NSCLC) | licensing - development - production - commercialisation | Cancer - Oncology | Licensing agreement |
| 2018-01-07 | Genzyme (USA - MA), a Sanofi company (France) - Alnylam Pharmaceuticals (USA - MA) | RNAi therapeutics including ALN-AT3, fitusiran, patisiran and ALN-TTRsc02 | rare genetic diseases including hemophilia A, hemophilia B | development - commercialisation | Rare diseases - Genetic diseases | Development agreement |
| 2018-01-05 | Takeda Pharmaceutical (Japan) Denali Therapeutics (USA - CA) | up to three specified therapeutic product candidates for neurodegenerative diseases | neurodegenerative disorders, including Alzheimer’s disease and other indications | collaboration - development - commercialisation | Neurodegenerative diseases | Development agreement |
| 2018-01-05 | Aduro Biotech (USA - CA) | chief financial officer | nomination | Cancer - Oncology | Nomination | |
| 2018-01-05 | Peregrine Pharmaceuticals, now Avid Bioservices (USA - CA) | restructuring | Technology - Services | Restructuring | ||
| 2018-01-05 | Retrotophin (USA - CA) Censa Pharmaceuticals (USA - MA) | CNSA-001 | phenylketonuria | development | Rare diseases - Genetic diseases - Metabolic diseases | Development agreement |
